Bcl-9 (B Cell CLL/Lymphoma 9, MGC131591)

Antibodies / Antibodies-Cancer Markers

-20°C

Supplied as a lyophilized powder from PBS, pH 7.4, 5% trehalose. Reconstitute with 200ul sterile PBS.

E. coli-expressed recombinant protein corresponding to Met1009-Gly1328 of human Bcl-9, aa1009- 1328 (UniProt accession #O00512).

Bcl-9 (B-cell lymphoma 9; also Protein legless homolog) is a 149kD transcriptional regulator that belongs to the Bcl-9 family of proteins. It is expressed in multiple tissues and serves to recruit Pygopus to the Wnt-pathway beta-catenin-TCF complex in the nucleus. Bcl-9 and Bcl-9-2 are considered evolutionary duplicates of Legless that perform the same task with different regulatory mechanisms. Human Bcl-9 is 1426aa in length. It contains one phosphothreonine and three phosphoserine sites, two poly-Pro regions (aa514-517 and 970-973), and one
poly-Ala segment (aa900-903). There is one potential alternate start site at Met27, and a variant isoform exists that shows a four aa substitution for aa 1391-1426. Over aa1009-1328, human Bcl-9 is 96% aa identical to mouse Bcl-9. B cell cancers often have translocations at the 3’UTR
region of the Bcl-9 gene.

Applications:
Suitable for use in Western Blot. Other applications not tested.

Recommended Dilution:
Western Blot: 0.5ug/ml
Optimal dilutions to be determined by the researcher.

Storage and Stability:
Lyophilized powder may be stored at -20°C. Stable for 12 months after receipt at -20°C. Reconstitute with sterile PBS. Aliquot to avoid repeated freezing and thawing. Store at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.